AMRN
Price
$16.00
Change
+$0.55 (+3.56%)
Updated
Sep 26 closing price
Capitalization
330.92M
SNY
Price
$45.54
Change
+$0.47 (+1.04%)
Updated
Sep 26 closing price
Capitalization
111.3B
26 days until earnings call
Interact to see
Advertisement

AMRN vs SNY

Header iconAMRN vs SNY Comparison
Open Charts AMRN vs SNYBanner chart's image
Amarin
Price$16.00
Change+$0.55 (+3.56%)
Volume$69.55K
Capitalization330.92M
Sanofi ADS
Price$45.54
Change+$0.47 (+1.04%)
Volume$13.18M
Capitalization111.3B
AMRN vs SNY Comparison Chart in %
Loading...
AMRN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AMRN vs. SNY commentary
Sep 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMRN is a Buy and SNY is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 29, 2025
Stock price -- (AMRN: $16.00 vs. SNY: $45.54)
Brand notoriety: AMRN: Notable vs. SNY: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: AMRN: 114% vs. SNY: 426%
Market capitalization -- AMRN: $330.92M vs. SNY: $111.3B
AMRN [@Pharmaceuticals: Major] is valued at $330.92M. SNY’s [@Pharmaceuticals: Major] market capitalization is $111.3B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $649.52B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.76B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMRN’s FA Score shows that 0 FA rating(s) are green whileSNY’s FA Score has 1 green FA rating(s).

  • AMRN’s FA Score: 0 green, 5 red.
  • SNY’s FA Score: 1 green, 4 red.
According to our system of comparison, SNY is a better buy in the long-term than AMRN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMRN’s TA Score shows that 4 TA indicator(s) are bullish while SNY’s TA Score has 5 bullish TA indicator(s).

  • AMRN’s TA Score: 4 bullish, 5 bearish.
  • SNY’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, SNY is a better buy in the short-term than AMRN.

Price Growth

AMRN (@Pharmaceuticals: Major) experienced а +4.23% price change this week, while SNY (@Pharmaceuticals: Major) price change was -4.41% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.20%. For the same industry, the average monthly price growth was -0.44%, and the average quarterly price growth was +12.50%.

Reported Earning Dates

SNY is expected to report earnings on Oct 24, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-1.20% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SNY($111B) has a higher market cap than AMRN($331M). AMRN YTD gains are higher at: 64.948 vs. SNY (-1.393). SNY has higher annual earnings (EBITDA): 12.6B vs. AMRN (-70.12M). SNY has more cash in the bank: 15.4B vs. AMRN (299M). AMRN has less debt than SNY: AMRN (7.34M) vs SNY (22.3B). SNY has higher revenues than AMRN: SNY (45.7B) vs AMRN (219M).
AMRNSNYAMRN / SNY
Capitalization331M111B0%
EBITDA-70.12M12.6B-1%
Gain YTD64.948-1.393-4,662%
P/E RatioN/A15.06-
Revenue219M45.7B0%
Total Cash299M15.4B2%
Total Debt7.34M22.3B0%
FUNDAMENTALS RATINGS
AMRN vs SNY: Fundamental Ratings
AMRN
SNY
OUTLOOK RATING
1..100
1778
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
4
Undervalued
PROFIT vs RISK RATING
1..100
10080
SMR RATING
1..100
9661
PRICE GROWTH RATING
1..100
4281
P/E GROWTH RATING
1..100
10094
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SNY's Valuation (4) in the Pharmaceuticals Major industry is significantly better than the same rating for AMRN (90) in the Pharmaceuticals Other industry. This means that SNY’s stock grew significantly faster than AMRN’s over the last 12 months.

SNY's Profit vs Risk Rating (80) in the Pharmaceuticals Major industry is in the same range as AMRN (100) in the Pharmaceuticals Other industry. This means that SNY’s stock grew similarly to AMRN’s over the last 12 months.

SNY's SMR Rating (61) in the Pharmaceuticals Major industry is somewhat better than the same rating for AMRN (96) in the Pharmaceuticals Other industry. This means that SNY’s stock grew somewhat faster than AMRN’s over the last 12 months.

AMRN's Price Growth Rating (42) in the Pharmaceuticals Other industry is somewhat better than the same rating for SNY (81) in the Pharmaceuticals Major industry. This means that AMRN’s stock grew somewhat faster than SNY’s over the last 12 months.

SNY's P/E Growth Rating (94) in the Pharmaceuticals Major industry is in the same range as AMRN (100) in the Pharmaceuticals Other industry. This means that SNY’s stock grew similarly to AMRN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AMRNSNY
RSI
ODDS (%)
N/A
Bullish Trend 3 days ago
66%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
50%
Momentum
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 3 days ago
53%
MACD
ODDS (%)
Bullish Trend 3 days ago
75%
Bearish Trend 3 days ago
50%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
75%
Bearish Trend 3 days ago
49%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
73%
Bearish Trend 3 days ago
41%
Advances
ODDS (%)
Bullish Trend 3 days ago
73%
Bullish Trend 11 days ago
51%
Declines
ODDS (%)
Bearish Trend 18 days ago
87%
Bearish Trend 4 days ago
49%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
85%
Bullish Trend 3 days ago
58%
Aroon
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
43%
View a ticker or compare two or three
Interact to see
Advertisement
AMRN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RCKT3.260.07
+2.19%
Rocket Pharmaceuticals
IDT62.570.82
+1.33%
IDT Corp
ICL6.090.08
+1.33%
ICL Group Ltd
ICCC6.03-0.01
-0.25%
ImmuCell Corp
NHPBP18.20-0.10
-0.55%
National Healthcare Properties Inc

AMRN and

Correlation & Price change

A.I.dvisor tells us that AMRN and OGN have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AMRN and OGN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMRN
1D Price
Change %
AMRN100%
+3.56%
OGN - AMRN
28%
Poorly correlated
+0.89%
PFE - AMRN
25%
Poorly correlated
+0.68%
SNY - AMRN
23%
Poorly correlated
+1.04%
BIIB - AMRN
22%
Poorly correlated
+1.25%
NVO - AMRN
22%
Poorly correlated
-0.77%
More

SNY and

Correlation & Price change

A.I.dvisor indicates that over the last year, SNY has been loosely correlated with GSK. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if SNY jumps, then GSK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SNY
1D Price
Change %
SNY100%
+1.04%
GSK - SNY
53%
Loosely correlated
+0.84%
NVS - SNY
51%
Loosely correlated
+1.16%
PFE - SNY
49%
Loosely correlated
+0.68%
AZN - SNY
48%
Loosely correlated
+0.31%
MRK - SNY
44%
Loosely correlated
+1.24%
More